(Q35050772)

6 August 2017

title

Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients (English)

1 reference

6 August 2017

1 reference

1 reference

7

Gad Rennert

1 reference

6 August 2017

Katerina Shulman

1

1 reference

6 August 2017

Ilana Cohen

2

1 reference

6 August 2017

Ofra Barnett-Griness

3

1 reference

6 August 2017

Abraham Kuten

4

1 reference

6 August 2017

Stephen B Gruber

5

1 reference

6 August 2017

Flavio Lejbkowicz

6

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 February 2011

1 reference

6 August 2017

1 reference

6 August 2017

volume

117

1 reference

6 August 2017

issue

14

1 reference

6 August 2017

page(s)

3156-3162

1 reference

Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer

6 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117027

Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117027

ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117027

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117027

Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117027

Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117027

UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117027

UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117027

Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117027

Statins and the risk of colorectal cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117027

"Irinogenetics" and UGT1A: from genotypes to haplotypes

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117027

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117027

Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3117027

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

8 July 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25735

UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25735

Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25735

UGT1A1 Polymorphism Can Predict Hematologic Toxicity in Patients Treated with Irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25735

The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21287524

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21287524

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/CNCR.25735

1 reference

6 August 2017

1 reference

6 August 2017

1 reference